Prostate Cancer Reports
54

Volume 5 Supplement 5
May 2017



Home > Prostate Cancer Reports > Volume 5, Year 2017 > Supplement 5, May


CONTENTS



CASE REPORTS
DIAGNOSIS AND EVALUATION
EPIDEMIOLOGY, RISK FACTORS AND PREVENTION
ETIOLOGY, PATHOGENESIS AND PATHOLOGY
FOLLOW-UP AND QUALITY OF LIFE
OVERALL MANAGEMENT
PROGNOSIS AND OUTCOMES
TREATMENT





CASE REPORTS



Dinerman BF, Bernstein AN, Khani F, Hu JC.
Intraductal Carcinoma of the Prostate: A Risk for Rapid Recurrence.
Urology. 2017 Mar 28. pii: S0090-4295(17)30293-5. doi: 10.1016/j.urology.2017.03.030. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Markowski MC, Imus P, Wright JL, Schottenstein D, Paller CJ.
Long-Term Control of Oligometastatic Prostate Cancer After Stereotactic Body Radiotherapy in the Absence of Androgen Deprivation Therapy: A Case Report.
Clin Genitourin Cancer. 2017 Feb 27. pii: S1558-7673(17)30044-7. doi: 10.1016/j.clgc.2017.02.001. [Epub ahead of print]
Source | Abstract | Full text | Similar articles





DIAGNOSIS AND EVALUATION



Emberton M.
An end to the phenomenon of 'upgrading' in early prostate cancer?
BJU Int. 2017 Apr;119(4):506-507. doi: 10.1111/bju.13671.
Source | Abstract | Full text | Similar articles




Fontenot PA Jr, Nehra A, Parker W, Wyre H, Mirza M, Duchene DA, Holzbeierlein J, Thrasher JB, Van Veldhuizen P, Lee EK.
Metastatic prostate cancer in the modern era of PSA screening.
Int Braz J Urol. 2017 Mar 24;43. doi: 10.1590/S1677-5538.IBJU.2016.0340. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Habl G, Sauter K, Schiller K, Dewes S, Maurer T, Eiber M, Combs SE.
68 Ga-PSMA-PET for radiation treatment planning in prostate cancer recurrences after surgery: Individualized medicine or new standard in salvage treatment.
Prostate. 2017 Jun;77(8):920-927. doi: 10.1002/pros.23347. Epub 2017 Mar 20.
Source | Abstract | Full text | Similar articles




McClinton C, Niroumand M, Sood S, Shah V, Hill J, Dusing RW, Shen X.
Patterns of lymph node positivity on 11C-acetate PET imaging in correlation to the RTOG pelvic radiation field for prostate cancer.
Pract Radiat Oncol. 2017 Mar 6. pii: S1879-8500(17)30063-2. doi: 10.1016/j.prro.2017.03.002. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Pessoa RR, Viana PC, Mattedi RL, Guglielmetti GB, Cordeiro MD, Coelho RF, Nahas WC, Srougi M.
Value of 3-Tesla multiparametric magnetic resonance imaging and targeted biopsy for improved risk stratification in patients considered for active surveillance.
BJU Int. 2017 Apr;119(4):535-542. doi: 10.1111/bju.13624. Epub 2016 Sep 3.
Source | Abstract | Full text | Similar articles





EPIDEMIOLOGY, RISK FACTORS AND PREVENTION



Papa NP, MacInnis RJ, English DR, Bolton D, Davis ID, Lawrentschuk N, Millar JL, Pedersen J, Severi G, Southey MC, Hopper JL, Giles GG.
Ejaculatory frequency and the risk of aggressive prostate cancer: Findings from a case-control study.
Urol Oncol. 2017 Mar 27. pii: S1078-1439(17)30107-2. doi: 10.1016/j.urolonc.2017.03.007. [Epub ahead of print]
Source | Abstract | Full text | Similar articles





ETIOLOGY, PATHOGENESIS AND PATHOLOGY



Humphrey PA.
Histopathology of Prostate Cancer.
Cold Spring Harb Perspect Med. 2017 Apr 7. pii: a030411. doi: 10.1101/cshperspect.a030411. [Epub ahead of print]
Source | Abstract | Full text | Similar articles





FOLLOW-UP AND QUALITY OF LIFE



Nead KT, Sinha S, Nguyen PL.
Androgen deprivation therapy for prostate cancer and dementia risk: a systematic review and meta-analysis.
Prostate Cancer Prostatic Dis. 2017 Mar 28. doi: 10.1038/pcan.2017.10. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Palumbo I, Matrone F, Montesi G, Bellavita R, Lupattelli M, Saldi S, Frattegiani A, Arena E, Mariucci C, Falcinelli L, Bini V, Aristei C.
Statins Protect Against Acute RT-related Rectal Toxicity in Patients with Prostate Cancer: An Observational Prospective Study.
Anticancer Res. 2017 Mar;37(3):1453-1457.
Source | Abstract | Full text | Similar articles




Venkatesan P.
Quality of life after treatments for prostate cancer.
Lancet Oncol. 2017 Mar 30. pii: S1470-2045(17)30244-9. doi: 10.1016/S1470-2045(17)30244-9. [Epub ahead of print]
Source | Abstract | Full text | Similar articles





OVERALL MANAGEMENT



Moschini M, Carroll PR, Eggener SE, Epstein JI, Graefen M, Montironi R, Parker C.
Low-risk Prostate Cancer: Identification, Management, and Outcomes.
Eur Urol. 2017 Mar 15. pii: S0302-2838(17)30174-4. doi: 10.1016/j.eururo.2017.03.009. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Pruthi DK, Ankerst DP, Liss MA.
Novel Definitions of Low-risk and High-risk Prostate Cancer: Implications for the European Randomized Study of Screening for Prostate Cancer Risk Assessment Tool.
Eur Urol. 2017 Feb 17. pii: S0302-2838(17)30098-2. doi: 10.1016/j.eururo.2017.02.009. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Roobol MJ, Verbeek JF, van der Kwast T, Kümmerlin IP, Kweldam CF, van Leenders GJ.
Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth.
Eur Urol. 2017 Feb 2. pii: S0302-2838(17)30058-1. doi: 10.1016/j.eururo.2017.01.033. [Epub ahead of print]
Source | Abstract | Full text | Similar articles





PROGNOSIS AND OUTCOMES



Beauval JB, Cabarrou B, Gandaglia G, Patard PM, Ouzzane A, de la Taille A, Soulié M, Briganti A, Ploussard G, Rozet F, Roumiguié M.
External validation of a nomogram for identification of pathologically favorable disease in intermediate risk prostate cancer patients.
Prostate. 2017 Jun;77(8):928-933. doi: 10.1002/pros.23348. Epub 2017 Apr 2.
Source | Abstract | Full text | Similar articles




Fontanella P, Benecchi L, Grasso A, Patel V, Albala D, Abbou C, Porpiglia F, Sandri M, Rocco B, Bianchi G.
Decision making tools in prostate cancer: from risk grouping to nomograms.
Minerva Urol Nefrol. 2017 Mar 30. doi: 10.23736/S0393-2249.17.02832-6. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Garzotto M.
Is Low-Risk Prostate Cancer More Indolent in Younger Patients?
J Clin Oncol. 2017 Mar 27:JCO2017723684. doi: 10.1200/JCO.2017.72.3684. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Howard LE, Moreira D, De Hoedt A, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Freedland SJ.
Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer.
BJU Int. 2017 Mar 28. doi: 10.1111/bju.13856. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Leapman MS, Cowan JE, Nguyen HG, Shinohara KK, Perez N, Cooperberg MR, Catalona WJ, Carroll PR.
Active Surveillance in Younger Men With Prostate Cancer.
J Clin Oncol. 2017 Mar 27:JCO2016680058. doi: 10.1200/JCO.2016.68.0058. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Leyh-Bannurah SR, Gazdovich S, Budäus L, Zaffuto E, Briganti A, Abdollah F, Montorsi F, Schiffmann J, Menon M, Shariat SF, Fisch M, Chun F, Steuber T, Huland H, Graefen M, Karakiewicz PI.
Local Therapy Improves Survival in Metastatic Prostate Cancer.
Eur Urol. 2017 Apr 3. pii: S0302-2838(17)30231-2. doi: 10.1016/j.eururo.2017.03.020. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Zhao SG, Chang SL, Spratt DE, Erho N, Yu M, Ashab HA, Alshalalfa M, Speers C, Tomlins SA, Davicioni E, Dicker AP, Carroll PR, Cooperberg MR, Freedland SJ, Karnes RJ, Ross AE, Schaeffer EM, Den RB, Nguyen PL, Feng FY.
Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis.
Lancet Oncol. 2016 Nov;17(11):1612-1620. doi: 10.1016/S1470-2045(16)30491-0. Epub 2016 Oct 12.
Source | Abstract | Full text | Similar articles





TREATMENT



Berruti A, Dalla Volta A.
Resistance to Hormonal Therapy in Prostate Cancer.
Handb Exp Pharmacol. 2017 Mar 29. doi: 10.1007/164_2017_21. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Carrie C, Hasbini A, de Laroche G, Richaud P, Guerif S, Latorzeff I, Supiot S, Bosset M, Lagrange JL, Beckendorf V, Lesaunier F, Dubray B, Wagner JP, N'Guyen TD, Suchaud JP, Créhange G, Barbier N, Habibian M, Ferlay C, Fourneret P, Ruffion A, Dussart S.
Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
Lancet Oncol. 2016 Jun;17(6):747-56. doi: 10.1016/S1470-2045(
16)00111-X. Epub 2016 May 6.
Source | Abstract | Full text | Similar articles




Chaussy CG, Thüroff S.
High-Intensity Focused Ultrasound for the Treatment of Prostate Cancer: A Review.
J Endourol. 2017 Apr;31(S1):S30-S37. doi: 10.1089/end.2016.0548. Epub 2017 Mar 29.
Source | Abstract | Full text | Similar articles




de Carvalho TM, Heijnsdijk EAM, de Koning HJ.
When should active surveillance for prostate cancer stop if no progression is detected?
Prostate. 2017 Apr 17. doi: 10.1002/pros.23352. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Henkenberens C, VON Klot CA, Ross TL, Bengel FM, Wester HJ, Katja H, Christiansen H, Derlin T.
68Ga-PSMA Ligand PET/CT-based Radiotherapy for Lymph Node Relapse of Prostate Cancer After Primary Therapy Delays Initiation of Systemic Therapy.
Anticancer Res. 2017 Mar;37(3):1273-1279.
Source | Abstract | Full text | Similar articles




Kumar SS, Pacey S.
The role of chemotherapy and new targeted agents in the management of primary prostate cancer.
J Clin Urol. 2016 Dec;9(2 Suppl):30-37. doi: 10.1177/2051415816685211. Epub 2016 Dec 1.
Source | Abstract | Full text | Similar articles




Lee WR.
Invited commentary on GETUG-AFU 16.
Transl Androl Urol. 2016 Dec;5(6):958-960. doi: 10.21037/tau.2016.11.10.
Source | Abstract | Full text | Similar articles




Parker C, Clarke N, Logue J, Payne H, Catton C, Kynaston H, Murphy C, Morgan R, Morash C, Parulekar W, Parmar M, Savage C, Stansfeld J, Sydes M; RADICALS Trial Management Group.
RADICALS (Radiotherapy and Androgen Deprivation in Combination after Local Surgery).
Clin Oncol (R Coll Radiol). 2007 Apr;19(3):167-71. Epub 2007 Feb 7.
Source | Abstract | Full text | Similar articles




Turpin A, Pasquier D, Massard C, Berdah JF, Culine S, Penel N.
First-line management of metastatic castrate-resistant prostate cancer patients: Audit of real-life practices.
Bull Cancer. 2017 Apr 5. pii: S0007-4551(17)30056-5. doi: 10.1016/j.bulcan.2017.02.002. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Williams S, Yaxley JW, Coughlin GD, Gardiner RA.
A randomised control trial of salvage radiotherapy and androgen deprivation therapy following prostatectomy: commentary on five year follow-up findings.
Transl Androl Urol. 2016 Dec;5(6):971-973. doi: 10.21037/tau.2016.11.15.
Source | Abstract | Full text | Similar articles




Woodrum DA, Kawashima A, Gorny KR, Mynderse LA.
Prostate cancer: state of the art imaging and focal treatment.
Clin Radiol. 2017 Apr 3. pii: S0009-9260(17)30075-2. doi: 10.1016/j.crad.2017.02.010. [Epub ahead of print]
Source | Abstract | Full text | Similar articles